Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Xtandi Re-Pricing Major Cause of Japan Sales Slump: Astellas President
Astellas Pharma’s 7.6% decline in half-year Japan sales is mainly attributed to a biennial drug price revision in April, especially a 25% re-pricing of its prostate cancer med Xtandi (enzalutamide), President Yoshihiko Hatanaka said on October 28. “The 25% price…
To read the full story
Related Article
- Astellas Sees Sales Drop, but Profits Grow on Lower Costs
October 31, 2016
BUSINESS
- J&J’s Tremfya Now Available for Self-Injection in IBD
June 2, 2026
- J&J Taps Leading Cancer Centers to Bolster Japan Trial Environment
June 2, 2026
- BMS Files Breyanzi for Relapsed/Refractory CLL, SLL in Japan
June 1, 2026
- Astellas Rebuts ISS Opposition to Outside Director Nominee
June 1, 2026
- Meiji Backs US Fund Supporting Pandemic Preparedness
June 1, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…